To date, there is no completed study on the effectiveness of nicotinamide mononucleotide (NMN) that has been conducted on humans. Nevertheless, promising in vivo-Studies (e.g. on the topic Fertility and NMN) and positive results of a security study the cornerstone for a new era of molecular research. Pioneers in this field are the researchers at EffePharm LTD., who have started the world's largest clinical NMN study with the product Uthever® NMN. We would like to give you a brief overview of the scientific study and introduce their research methods:
Overview
The aim of the study is to evaluate the efficacy and safety of Uthever® NMN (nicotinamide mononucleotide, a form of vitamin B3). For this purpose, 66 healthy subjects (male and female) between the ages of 40 and 65. After an initial physical examination, all 66 subjects are randomly (or as the expert says, randomized) into two groups. While the participants in the first group take 300 mg of Uthever® NMN in the form of two capsules daily, the other group receives the same amount of capsules with starch powder as a placebo. Neither the test subjects nor the scientific instructors know which capsules actually contain NMN. This study design is literally called "double-blind". The study participants have to swallow the capsules with water every day after breakfast for a period of 60 days. During the study, the test subjects are asked to keep regular notes on the dosage taken and their state of health.
Important key points
After one month (day 30) and at the end of the period (day 60), the participants return to the clinic to review and collect their data. At all visits, efficacy and safety assessments of NMN are carried out and possible side effects are monitored. Furthermore, a thorough assessment of the test subjects is carried out using the SF-36 questionnaire (to check the state of health) and a physical examination. In addition to the assessment of the classic vital functions such as heart activity, pulse analysis or blood pressure, this also includes a precise laboratory blood test. The blood count analyzes the lipid level and insulin resistance, as well as the functional parameters of the lungs and liver. The cellular NAD +- and NADH concentration in serum is also determined to confirm the ability of Uthever® NMN to increase NAD levels in the human body.
outlook
Quite a lot! But the more the better. But as we can see from this research project, the focus is not only on quantity, but also on quality. The scientific design (randomized, double-blind, placebo-controlled) suggests a highly evidence-based study (evidence level Ib). We are all the more excited about the results. But what about the study's progress? Despite the many disruptions caused by the COVID-19 pandemic, the recruitment phase was recently completed. So it can't be long now! We look forward to the findings of this study - but as the saying goes: anticipation is the greatest joy.
Sources
Books
EffePharm LTD. A Multicentre, Randomized, Double Blind, Parallel Design, Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever (NMN), an Orally Administered Supplementation in Middle Aged and Older Adults. https://www.clinicaltrials.gov/ct2/show/NCT04228640?term=NMN&draw=2&rank=1
graphics
The graphics were purchased under license from Canva and are marked accordingly.
